221 Development of abatacept- and adalimumab-specific predictive models of response to therapy in rheumatoid arthritis using data from a head-to-head study

Clicks: 194
ID: 117688
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Background: Highly effective, targeted DMARD therapies with different mechanisms of action are available for RA. Translating precision medicine into clinical practice requires treatment-specific predictive models, with a goal of individualised, targeted therapy. Therefore, we created separate predictive models for response to abatacept or adalimumab, using baseline biomarker data from the head-to-head AMPLE study.
Reference Key
connolly2018rheumatology221 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Somnath Bandyopadhyay,Michael A Maldonado,Ron Ammar,Michael Schiff,Michael Weinblatt,Roy Fleischmann,Sean E Connolly;Somnath Bandyopadhyay;Michael A Maldonado;Ron Ammar;Michael Schiff;Michael Weinblatt;Roy Fleischmann;Sean E Connolly;
Journal rheumatology
Year 2018
DOI
10.1093/rheumatology/key075.445
URL
https://sciprofiles.com/publication/view/f2eb235dbe51e16b316e759507fc0834
Keywords
treatment ample abatacept and adalimumab data from a head predictive models of response

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.